Mesenchymal-epithelial transition factor (MET), also known as c-Met or Hepatocyte growth factor receptor (HGFR), is a receptor tyrosine kinase (RTK) that is overexpressed or mutated in various malignancies. Aberrantly active MET triggers tumor growth, angiogenesis, and cancer metastasis. MET activity is also critical to embryogenesis.
HGF, also known as scatter factor (SF), is the only known ligand of MET. Upon activation, MET engages with a variety of signal transducers at its intracellular multisubstrate docking site to stimulate the Ras/MAPK, JAK/STAT, SRC, PI3K/AKT, Wnt/β-catenin, and other signaling pathways. MET and its associated signaling pathways are clinically important therapeutic targets. A number of small-molecule inhibitors and antibodies targeting MET and HGF are being developed as promising therapeutics for cancer, heart disease, autism, and other diseases. Sino Biological has developed high-quality reagents to support the study of MET signaling. Read more...
No comments:
Post a Comment